Drugs / Vayarin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02348073 Comparator | Mar 2015 → Oct 2018 | attention deficit hyperactivity disorder, inattentive type, epilepsy | Hospices Civils de Lyon | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vayarin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02348073 ↗ |
| Modality | Other / unclassified | “dietary n-3 fatty acids, containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) conjugated to a phospholipid vector” NCT02348073 ↗ |